XTalks

MARCH 8, 2024

Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications. It occurs when the formation of new bone doesn’t keep up with the loss of old bone. The disease often progresses without symptoms until a fracture happens, typically in the wrist, hip or spine.

Drugs 59

Drugs FDA Approval Production Immune Response 59

The Pharma Data

DECEMBER 31, 2020

The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. In mid-December, the FDA approved Orgovyx (relugolix), the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for men with advanced prostate cancer.

Vaccination 52

Vaccination Vaccine FDA Approval Hormones 52

Find Me Cure

OCTOBER 13, 2019

CDK4/6 inhibitors are used alongside hormone therapy. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials. Some kinds of cancer can protect themselves from being attacked by the immune system by stimulating proteins that keep the immune response in check.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

The Pharma Data

JULY 23, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Hormones 52

Hormones Trials Genomics Genome 52

The Pharma Data

MARCH 11, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Genomics Genome 52

XTalks

NOVEMBER 12, 2024

Pancreatic cancer occurs when cells in the pancreas, a vital organ responsible for producing enzymes and hormones, begin to grow uncontrollably. This approval allows Onivyde to be used earlier in the treatment process, offering new options for patients with advanced disease. percent, a median duration of response of 12.6

Research 104

Research FDA Approval Trials Clinical Trials 104